Analysis of survival and influencing factors of patients with primary gastric-diffuse large B cell lymphoma
WANG Yufang;KE Jinyong;KE Shandong;Department of Hematopathology,Central Hospital of Huangshi,E'dong Medical Group;
Objective To explore the survival of patients with primary gastric-diffuse large B cell lymphoma(PG-DLBCL) and its influencing factors. Method Clinical data of 184 patients with PG-DLBCL were analyzed retrospectively.The therapeutic regimen, clinical data and follow-up data were recorded and collected. Survival of PG-DLBCL patients was calculated by plotting Kaplan-Meier survival curves; univariate and multivariate Cox analysis were used to analyze factors that may affect the survival of patients with PG-DLBCL. Result At the end of the 5-year follow-up period, 4 patients(2.2%) withdrew and 125 patients(67.9%) survived, the rest 55 patients(29.9%) were all died of PG-DLBCL progression. Kaplan-Meier survival curves showed that the overall survival rates at 1 year, 3 years and 5 years were 88.3%,71.5% and 67.9%, respectively. Univariate Cox proportional hazards model showed that, Lugano staging, B symptoms,HGB level, ALB level, LDH level, β2 microglobulin level, combined with rituximab, Hp infection had significantly effects on the prognosis of patients(P0.05). However, gender, age, cell origin had no effect on the prognosis of patients(P0.05). The results of multivariate Cox regression showed that the prognosis of patients with PG-DLBCL was not affected by symptoms of B, HGB level, ALB level, β2 microglobulin level and Hp infection(P0.05), but Lugano staging,LDH level and rituximab were independent prognostic factors(RR=2.323, 1.792, 0.399, P0.05). Conclusion Lugano stage III-IV and elevated LDH level are independent risk factors for the prognosis of patients with PG-DLBCL, combined with rituximab can increase the survival rate of patients.
【CateGory Index】： R735.2